ACRV
Acrivon Therapeutics, Inc. Common Stock
NASDAQ · Healthcare · Biotechnology · US
$2.13
+3.40%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | (528.0K) | 1.4M | 1.0M | 536.0K | — |
| Gross Profit | 528.0K | (1.4M) | (1.0M) | (536.0K) | — |
| Operating Expenses | |||||
| R&D Expense | 57.3M | 60.0M | 64.0M | 45.5M | 23.9M |
| SG&A Expense | 21.0M | 24.1M | 25.2M | 21.2M | 8.7M |
| General & Admin Expense | 21.0M | 24.1M | 25.2M | 21.1M | 8.7M |
| Selling & Marketing Expense | — | — | — | 134.0K | — |
| Other Expenses | 611.0K | (1.4M) | (1.0M) | — | — |
| Total Operating Expenses | 78.9M | 82.8M | 88.2M | 66.7M | 32.7M |
| Cost and Expenses | 78.4M | 84.1M | 89.2M | 67.2M | 32.7M |
| Operating Income (EBIT) | (78.4M) | (84.1M) | (89.2M) | (67.2M) | (32.7M) |
| Non-Operating | |||||
| Interest Income | 4.6M | 6.5M | 9.2M | 7.0M | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 4.6M | 6.5M | 9.2M | 7.0M | — |
| Other Non-Op Income/Expense | 4.1M | 6.2M | 8.6M | 6.8M | 1.5M |
| Non-Operating Income (excl Interest) | 2.1M | (6.2M) | (8.6M) | (6.8M) | (1.5M) |
| EBT (Pre-Tax Income) | (74.2M) | (77.9M) | (80.6M) | (60.4M) | (31.2M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (74.2M) | (77.9M) | (80.6M) | (60.4M) | (31.2M) |
| Earnings from Cont. Ops | (74.2M) | (77.9M) | (80.6M) | (60.4M) | (31.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (74.2M) | (77.9M) | (80.6M) | (60.4M) | (31.2M) |
| Per Share | |||||
| Basic EPS | ($1.88) | ($2.02) | ($2.10) | ($2.74) | ($1.42) |
| Diluted EPS | ($1.88) | ($2.02) | ($2.10) | ($2.74) | ($1.42) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 41.8M | 38.5M | 38.3M | 22.1M | 21.9M |
| Diluted Shares Outstanding | 41.8M | 38.5M | 38.3M | 22.1M | 21.9M |
| Profitability Metrics | |||||
| EBITDA | (78.9M) | (76.5M) | (79.5M) | (59.9M) | (30.8M) |
| D&A | 1.5M | 1.4M | 1.0M | 536.0K | 364.0K |
| EBIT | (80.4M) | (77.9M) | (80.6M) | (60.4M) | (31.2M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026